戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n of the regional changes in common advanced myocardial disease.
2 easures of function, suggestive of occult RV myocardial disease.
3  with Duchenne muscular dystrophy with early myocardial disease.
4 e to be an effective therapeutic strategy in myocardial disease.
5 icient forward cardiac output resulting from myocardial disease.
6 diseases including cancer, inflammation, and myocardial disease.
7 rt failure and implicate novel mechanisms of myocardial disease.
8 ged and thus opportunity to treat underlying myocardial disease.
9 male; mean age, 48 years) without structural myocardial disease.
10  define the onset and molecular mechanism of myocardial disease.
11  (chromosome 1p1-1q1) cardiac conduction and myocardial disease.
12  (chromosome 1p1-1q1) cardiac conduction and myocardial disease.
13 iles for further study in different types of myocardial disease.
14 are etiological agents of human inflammatory myocardial disease.
15 ion and the presence or absence of intrinsic myocardial disease.
16 ) is the gold standard for imaging suspected myocardial disease.
17 nd optimize patient outcomes in this complex myocardial disease.
18        These findings suggest an MVP-related myocardial disease.
19 ells (MSCs) have the potential to treat many myocardial diseases.
20  in oncology but has not yet been applied to myocardial diseases.
21 atification, and management of patients with myocardial diseases.
22 ging tools for their study in the context of myocardial diseases.
23 hed cardiac magnetic resonance parameters in myocardial diseases.
24 Fibrosis is observed in nearly every form of myocardial disease(1).
25 ), ischemic heart disease (91), infiltrative myocardial disease (59), hypertension (49), human immuno
26 ents with cardiomyopathy due to infiltrative myocardial disease (adjusted hazard ratio, 4.40; 95 perc
27 ation between E/E' and PCWP in patients with myocardial disease, an inverse relationship was found in
28 ardiac disease have evolved to conceptualize myocardial disease and patient vulnerability based on th
29  major potential for clinical application in myocardial disease and regenerative therapies.
30  difficult to differentiate from restrictive myocardial disease and severe tricuspid regurgitation.
31 f constrictive pericarditis from restrictive myocardial disease and severe tricuspid regurgitation.
32  plays a central role in the pathogenesis of myocardial disease and that reactive oxygen species is c
33 o opens many possibilities for investigating myocardial disease and therapeutic intervention at the c
34          Early initiation greatly attenuated myocardial disease and, for the first time with these dr
35 a) isoforms are upregulated and activated in myocardial diseases and have an important role in cardia
36 rhythmias presenting in the absence of known myocardial disease are often labelled as idiopathic, or
37         Sudden arrhythmic death syndrome and myocardial diseases are the most common conditions diagn
38 r cardiomyopathy (ARVC) is a rare, heritable myocardial disease associated with the development of ve
39       These forces are affected by intrinsic myocardial disease but should be preserved when diastole
40 n-CMR imaging but showed clinically relevant myocardial disease by CMR imaging.
41 med to investigate whether detecting diffuse myocardial disease by T1 mapping can discriminate betwee
42  in HF in which insights into the biology of myocardial disease can be matched to an understanding of
43 ardiomyopathy (ARVC) is an inherited genetic myocardial disease characterized by fibrofatty replaceme
44 tum cardiomyopathy is a pregnancy-associated myocardial disease characterized by the development of h
45 mendations [10%]), whereas heart failure and myocardial disease contained the least (9 of 315 recomme
46 ), interventions reducing the progression of myocardial disease could affect survival.
47             Hypertrophic cardiomyopathy is a myocardial disease defined by an increased left ventricu
48 c obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall
49 hance the diagnostic yield of T1 mapping for myocardial disease detection and classification.
50 vidence on the role of TGFbeta signalling in myocardial diseases, focusing on cellular targets and mo
51 d wild-type mice matched for the severity of myocardial disease further confirmed that pericarditis,
52 th hypertension/obesity related hypertrophic myocardial disease harbor potentially disease associated
53 sts that assess for subclinical coronary and myocardial disease have low sensitivity, and altered hem
54 nt insights into molecular genetic causes of myocardial diseases have highlighted the importance of s
55 ents with cardiomyopathy due to infiltrative myocardial diseases, HIV infection, or doxorubicin thera
56 aphy in healthy volunteers versus those with myocardial diseases (ie, cardiac amyloidosis [CA] and hy
57 etic resonance, subclinical inflammation and myocardial disease in asymptomatic HIV-infected individu
58    T2 mapping delineated a greater extent of myocardial disease in both conditions compared with that
59  role for T1 mapping in detection of diffuse myocardial disease in early disease stages and complemen
60 investigate plaque histology and concomitant myocardial disease in sudden coronary death.
61 sms and clinical phenotype of HIV-associated myocardial disease in the current era.
62 ors for coronary artery disease or different myocardial diseases in the absence of angiographically d
63                                      Diffuse myocardial disease is a characteristic feature in HCM, a
64 c sudden cardiac death (SCD) due to acquired myocardial diseases is unclear.
65 e genetic variants to the extent of acquired myocardial diseases leading to SCD.
66                                              Myocardial disease manifesting predominantly as cardiomy
67  of the molecular underpinnings of monogenic myocardial disease may help identify therapeutic targets
68 l-cause mortality across AI-ECG LVDF-derived myocardial disease (MD) grades in MR.
69 ntricular cardiomyopathy (ARVC) is a primary myocardial disease of incompletely resolved pathogenesis
70 ted cardiomyopathy (IDC) is a common primary myocardial disease of unknown etiology characterized by
71 e a family history of syncope, sudden death, myocardial disease or arrhythmias.
72 h patients (n=36) diagnosed with restrictive myocardial disease or severe tricuspid regurgitation aft
73 ancies in the association of enterovirus and myocardial disease, partially due to lack of data on the
74    The mechanisms linking ACTN2 mutations to myocardial disease phenotypes are unknown.
75 th non-CMR-based imaging, a new or alternate myocardial disease process may be identified in half of
76 icates that microRNAs (miRs) are involved in myocardial disease processes, we also investigated wheth
77 low-up protocols in early ARVC by evaluating myocardial disease progression in different age groups.
78 ike AS that should be considered as a global myocardial disease rather than an isolated valve disease
79 revealed that such compromise was related to myocardial disease (related to hypertension, stiff vesse
80 ant pericytes, their fate and involvement in myocardial disease remains unknown.
81 re also present in patients with restrictive myocardial disease (RMD).
82 link deformation abnormalities to underlying myocardial disease substrates, Digital Twins were create
83 g is useful in diagnosing acute inflammatory myocardial diseases, such as myocarditis and tako-tsubo
84  longitudinal strain and elevated markers of myocardial disease (T1 and T2 relaxation times, ECV, and
85 ghlighting unique features of NMD-associated myocardial disease that require clinicians to tailor the
86 rdiomyocyte proliferation may be involved in myocardial diseases that affect this population, and tha
87 cardiomyopathies are a heterogenous group of myocardial diseases that vary according to pathogenesis,
88  radiomics was significantly associated with myocardial disease type (chi(2) = 55.98, p < 0.0001).
89 ments for studies related to a wide range of myocardial diseases using lab-on-chip technology.
90 pathy and atrial myopathy as contributors to myocardial disease warrant incorporation of aortic and a
91 d displays to evaluate the extent of CAD and myocardial disease was assessed, and utility of coregist
92                                              Myocardial disease was detected in 40% of cases, includi
93                The prevalence of concomitant myocardial disease was high and independent of associate
94                                     Relevant myocardial disease was identified in 51% of patients usi
95 oung athletes (</= 35 years of age), whereas myocardial disease was more common in older individuals.
96  fibroblasts are a source of NO inflammatory myocardial diseases, we have studied the effect of cytok
97                                              Myocardial diseases were detected in 163 cases (22%), in
98 new light on the emerging role of T cells in myocardial diseases, which primarily affect the elderly
99                      Gene therapy for common myocardial diseases will require effective and homogeneo
100 ardiomyopathy is a genetically heterogeneous myocardial disease with >1000 causal variants identified
101 pertrophic cardiomyopathy (HCM) is a primary myocardial disease with a prevalence of 1 in 500 in huma
102 rtrophic cardiomyopathy (HCM) is a heritable myocardial disease with age-related penetrance.
103 r obesity as the most likely explanation for myocardial disease with hypertrophy and fibrosis.
104 diomyopathy (PPCM) is a pregnancy-associated myocardial disease with marked left ventricular systolic
105 ction delay is associated with more advanced myocardial disease, worse left ventricular (LV) function

 
Page Top